Home | miyaokalab

Genome Editing in Human iPS Cells to Study and Cure Disease

Human iPS (induced pluripotent stem) cells have the potential to allow us to study diseases in virtually any type of human cell, and develop cell transplantation-based therapies. Our team is developing and improving genome editing technology in iPS cells. We are developing novel isogenic iPS cell-based disease models, and correcting mutations in iPS cells from patients, a critical step in transplantation-based therapies. Our current focus is on diseases affecting cardiomyocytes and hepatocytes. →More

English

日本語

News

2021. 11. 25.　Anri Saitoh wins the Ochanomizu University Outstanding Student Award in Biology.

2021. 11. 18.　Kanata Imamura and Yuga Yasuda join the lab as interns.

2021. 11. 10.　Miyaoka answers a question on liver regeneration in Kodomo no Kagaku (Kids' Science magazine).

2021. 11. 3.　Genome edited iPS cell-based study on pathogenic mechanism of cardiomyopathy by RBM20 mutations is published in Nature Communications.

We revealed surprising smilarlities between cardiomyopathy and neurodgenerative diseases such as ALS (PDF).

Press relsease by Cincinnati Children's Hospital.

2021. 10. 5.　A review on CRISPR-Cas9 by Nakajima and Miyaoka is published in Clinical Immunology & Allergology (in Japanese)

2021. 9. 1.　Miyaoka is now affiliated with Ochanomizu University as an associate professor

2021. 8. 10.　Genome edited iPS cell-based study on pathogenic mechanism and therapeutic approaches of Wilson's disease is out at bioRxiv - Collaborative project with Dr. Yohei Hayashi at RIKEN BRC.